Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WASIM E DEEB

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1881700698
CMS profile
175766
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$58,317.94

412 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 9; records 51–100 of 412 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WASIM E DEEB

NPI 1881700698 · CMS profile ID 175766

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 9; records 51–100 of 412 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881700698?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WASIM E DEEB, NPI 1881700698, CMS profile ID 175766. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 9; records 51–100 of 412 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881700698?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). WASIM E DEEB, NPI 1881700698, CMS profile ID 175766. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 9; records 51–100 of 412 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881700698?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
WASIM E DEEB, NPI 1881700698, CMS profile ID 175766, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 9; records 51–100 of 412 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1881700698?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

412 matching records · $58,317.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 412 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 412.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $0.4411/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818781861 CMS
Xeris Pharmaceuticals, Inc. $17.1211/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837418337 CMS
Novo Nordisk Inc $18.6311/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810742309 CMS
Amgen Inc. $13.7211/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825865359 CMS
Clarus Therapeutics Inc. $13.2211/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855034809 CMS
Novo Nordisk Inc $13.9811/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811414865 CMS
Endo Pharmaceuticals Inc. $14.5811/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 828667375 CMS
Insulet Corporation $13.6811/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839836361 CMS
Amneal Pharmaceuticals LLC $15.9611/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829651897 CMS
Insulet Corporation $280.0011/01/2021 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839835559 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.8511/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849997929 CMS
Insulet Corporation $125.0010/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839835561 CMS
MannKind Corporation $5.8910/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821053497 CMS
MannKind Corporation $5.8910/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821053501 CMS
Merck Sharp & Dohme Corporation $16.5910/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848704745 CMS
Novartis Pharmaceuticals Corporation $21.4010/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812654359 CMS
Novo Nordisk Inc $2,210.0010/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811103102 CMS
Novo Nordisk Inc $122.5310/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811414475 CMS
Clarus Therapeutics Inc. $4.5410/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855035173 CMS
Insulet Corporation $12.2210/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839836363 CMS
DEXCOM, INC. $19.9110/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845274609 CMS
LifeScan, Inc. $16.1510/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845334153 CMS
Becton, Dickinson and Company $12.8910/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836116289 CMS
Insulet Corporation $13.9810/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839836367 CMS
MannKind Corporation $18.5210/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821053489 CMS
MannKind Corporation $18.5210/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821053493 CMS
Novo Nordisk Inc $18.7610/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811414469 CMS
Novo Nordisk Inc $23.3610/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810742305 CMS
Novo Nordisk Inc $0.2710/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811103095 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.6910/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763657722 CMS
Lilly USA, LLC $2.0610/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818802891 CMS
Lilly USA, LLC $5.4610/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818818261 CMS
SANOFI-AVENTIS U.S. LLC $2,310.0010/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843508023 CMS
SANOFI-AVENTIS U.S. LLC $346.5010/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843508027 CMS
SANOFI-AVENTIS U.S. LLC $111.5010/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843508029 CMS
Zealand Pharma US, Inc. $23.7510/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 800225941 CMS
Insulet Corporation $27.4810/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839836369 CMS
Novo Nordisk Inc $2,210.0010/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810627431 CMS
Novo Nordisk Inc $121.1210/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810742301 CMS
AstraZeneca Pharmaceuticals LP $16.1710/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834333761 CMS
Insulet Corporation $280.0010/11/2021 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839835557 CMS
Antares Pharma, Inc. $11.3610/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827479373 CMS
Amgen Inc. $11.5110/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825865355 CMS
Novo Nordisk Inc $21.4310/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811414465 CMS
Abbott Laboratories $20.9210/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815729529 CMS
Novartis Pharmaceuticals Corporation $19.6210/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812654357 CMS
Insulet Corporation $11.8110/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839836371 CMS
MannKind Corporation $1.2910/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821053473 CMS
MannKind Corporation $12.8910/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821053477 CMS
MannKind Corporation $1.2910/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821053481 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $70,032.85 324
PY2020 $17,122.48 295
PY2021 $58,317.94 412
PY2022 $56,054.72 330
PY2023 $19,338.31 278
PY2024 $26,772.73 258
PY2025 $37,978.38 244

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $597,413.02 47
PY2024 Principal investigator $497,328.55 115
PY2023 Principal investigator $98,287.19 59
PY2019 Principal investigator $24.96 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH JACKSONVILLE
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202533823
Principal investigator 1 ABBVIE INC. $168.00 12/31/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202535163
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 12/18/2025 Non-covered Recipient Entity
East Coast Institute For Research-Southside
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998263
Principal investigator 1 Boehringer Ingelheim International GmbH $699.30 12/17/2025 Non-covered Recipient Entity
East Coast Institute For Research-Southside
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767577
Principal investigator 1 Boehringer Ingelheim International GmbH $4.20 12/17/2025 Non-covered Recipient Entity
East Coast Institute For Research-Southside
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767579
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $25,012.00 12/15/2025 Non-covered Recipient Entity
ECIR Intermediate II LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220815131
Principal investigator 1 ABBVIE INC. $14,636.30 12/05/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529256
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 12/01/2025 Non-covered Recipient Entity
East Coast Institute for Research Jacksonville - S
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508493
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-Southside
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767575
Principal investigator 1 ABBVIE INC. $29,962.80 11/05/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522651
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17,051.00 11/05/2025 Non-covered Recipient Entity
East Coast Institute for Research Jacksonville - S
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508497
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,377.40 11/05/2025 Non-covered Recipient Entity
East Coast Institute for Research Jacksonville - S
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508500
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-Southside
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767573
Principal investigator 1 ABBVIE INC. $22,111.60 10/09/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202514425
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-Southside
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767571
Principal investigator 1 Abbott Laboratories $712.50 09/25/2025 Non-covered Recipient Entity
East Coast Institute for Research
ISM2411001A--Prolongation of GLP-1 Adherence when using Continuous Glucose Monitoring No dispute reported 06/30/2026 1248157744
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,790.00 09/24/2025 Non-covered Recipient Entity
ECIR MEDICAL COMMUNICATIONS
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185548137
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 09/19/2025 Non-covered Recipient Entity
East Coast Institute For Research-Southside
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998261
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 09/15/2025 Non-covered Recipient Entity
East Coast Institute For Research-Southside
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220814221
Principal investigator 1 ABBVIE INC. $16,161.60 09/04/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509326
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-Southside
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767565
Principal investigator 1 Abbott Laboratories $1,318.10 08/29/2025 Non-covered Recipient Entity
East Coast Institute for Research
ISM2411001A--Prolongation of GLP-1 Adherence when using Continuous Glucose Monitoring No dispute reported 06/30/2026 1248154770
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 08/26/2025 Non-covered Recipient Entity
East Coast Institute For Research-Southside
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767567
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
East Coast Institute For Research-Southside
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767569
Principal investigator 1 ABBVIE INC. $30,354.80 08/06/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503007
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 08/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-Southside
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767557
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-Southside
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767559
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 08/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-Southside
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767561
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 08/01/2025 Non-covered Recipient Entity
East Coast Institute For Research-Southside
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220767563
Principal investigator 1 ABBVIE INC. $2,570.80 07/29/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202500354
Principal investigator 1 ABBVIE INC. $8,878.80 07/16/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202498410
Principal investigator 1 AstraZeneca UK Limited $152,256.00 07/16/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH, LLC
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight or Obesity No dispute reported 06/30/2026 1185548139
Principal investigator 1 Abbott Laboratories $2,252.10 07/09/2025 Non-covered Recipient Entity
East Coast Institute for Research
ISM2411001A--Prolongation of GLP-1 Adherence when using Continuous Glucose Monitoring No dispute reported 06/30/2026 1248152200
Principal investigator 1 ABBVIE INC. $24,644.20 07/02/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495561
Principal investigator 1 ABBVIE INC. $5,000.00 07/02/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495563
Principal investigator 1 Alnylam Pharmaceuticals Inc. $150.50 07/02/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510504
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,505.00 07/02/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510508
Principal investigator 1 ABBVIE INC. $44,830.80 06/03/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202487701
Principal investigator 1 Abbott Laboratories $5,822.30 05/28/2025 Non-covered Recipient Entity
East Coast Institute for Research
ISM2411001A--Prolongation of GLP-1 Adherence when using Continuous Glucose Monitoring No dispute reported 06/30/2026 1248150590
Principal investigator 1 ABBVIE INC. $56.00 05/22/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202485765
Principal investigator 1 ABBVIE INC. $16,443.00 05/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202482531
Principal investigator 1 ABBVIE INC. $19,689.60 04/03/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202471565
Principal investigator 1 Insulet Corporation $3,500.00 03/26/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH,
Safety and Efficacy of the OmnipodTM 5 Automated Insulin Delivery System in Adults with Type 2 Diabetes No dispute reported 06/30/2026 1206961819
Principal investigator 1 ABBVIE INC. $35,854.70 03/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202460431
Principal investigator 1 ABBVIE INC. $16,385.60 02/06/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202449262
Principal investigator 1 Novartis Pharmaceuticals Corporation $34,425.87 01/27/2025 Non-covered Recipient Entity
EAST COAST RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190312561
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,216.00 01/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190300179